An mRNA vaccine candidate against the human immunodeficiency virus (HIV), developed by the National Institute of Allergy and Infectious Diseases, Moderna and other institutes, shows a 79% efficacy rate and no major side effects in animal trials on rhesus macaques, according to a peer-reviewed paper published in "Nature Medicine". ([https:--www.france24.com-en-live-news-20211209-experimental-mrna-vaccine-for-hiv-shows-promise-in-animals France24-AFP])
An mRNA vaccine candidate against the human immunodeficiency virus, developed by the National Institute of Allergy and Infectious Diseases, Moderna and other institutes, shows a 79% efficacy rate and no major side effects in animal trials on rhesus macaques, according to a peer-reviewed paper published in "Nature Medicine".